Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

摘要: In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane™) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM). parallel, also what extent outcomes from this trial correlated findings studies utilizing two murine intracerebral GBM models, U87MG and U251HF, predictive value these models. 25 patients were studied at recurrence. Stable disease, which occurred 44% patients, best response. The median progression-free survival (PFS) 8 weeks, PFS 6 months only 19%. For stable 24 weeks. toxicity profile unremarkable. modest effect on seen study agreed recent another study, showed 19% treated 13-cRA alone. Thus, combination is not more effective than progressive GBM. model found that long-term dosing or alone did increase animals tumors but modestly increased U251HF tumors. There no evidence synergism between drugs. From this, concluded animal generally predicted agents would have additive when given patients.